Metabolic Syndrome
Conditions
Brief summary
The objective of this study was to establish a formulation, containing both Hibiscus sabdariffa L. (HS) and Lippia citriodora L. (LC) extracts (Metabolaid®) that had significant capacity to activate the AMPK-enzyme and to reduce triglyceride accumulation in the hypertrophied adipocyte model. Then, we assessed the efficacy of this combination in light-to-moderate-overweight subjects under risk of developing metabolic syndrome.
Detailed description
AMP-activated protein kinase (AMPK) has been postulated as a molecular target in the amelioration of obesity-related diseases, where most therapeutic approaches have failed. Plant-polyphenols have shown the capacity to ameliorate obesity-induced metabolic disturbances. A combination of polyphenols (LC-HS) derived from Hibiscus sabdariffa L. (HS) and Lippia citriodora L. (LC) (lemon verbena) (Metabolaid®) was assessed for triglyceride accumulation and AMPK activation in the hypertrophied adipocyte model 3T3-L1. A dietary supplement containing 500 mg of LC-HS was evaluated in a double blind, placebo-controlled and randomized trial in 56 overweight subjects for two months. Anthropometric and circulating biochemical parameters were determined.
Interventions
DIETARY_SUPPLEMENTMetabolaid®
500 mg per day, in fasting conditions.
DIETARY_SUPPLEMENTPlacebo
500 mg per day, in fasting conditions.
Sponsors
Monteloeder SL
Universidad Miguel Hernandez de Elche
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Caregiver)
Eligibility
Sex/Gender
FEMALE
Age
36 Years to 69 Years
Healthy volunteers
Yes
Inclusion criteria
* Participants with a body mass index (BMI) from 24 to 34 kg/m2
Exclusion criteria
* total cholesterol lower than 200 mg/dL. * use of prescription medication for cholesterol or hypertension. * presence of any obesity-related pathology. * hormone replacement therapy. * consumption of antioxidant supplements/drugs. * alcohol addiction. * women who were pregnant or lactating.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in body Weight, using a weight scale | At the beginning, four weeks and end of the intervention, total eight weeks. | In Kg |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| BMI, calculated based on Weight and Height | At the beginning, four weeks and eight weeks | in kg/m\^2 |
| Waist Circumference, using a measuring tape | At the beginning, four weeks and eight weeks | in kg/m\^2 |
| Glucose | At the beginning, four weeks and eight weeks | Blood Sampling in Fasting conditions, in mg/dl |
| Tryglicerides | At the beginning, four weeks and eight weeks | Blood Sampling in Fasting conditions, in mg/dl |
| Height, using measuring tape | At the beginning, four weeks and eight weeks | In cm |
| HDL Cholesterol | At the beginning, four weeks and eight weeks | Blood Sampling in Fasting conditions, in mg/dl |
| Total Cholesterol | At the beginning, four weeks and eight weeks | Blood Sampling in Fasting conditions, in mg/dl |
| Blood Pressure | At the beginning, four weeks and eight weeks | Single Blood Pressure measurements, using the Omron M6 Comfort device |
| Heart rate | At the beginning, four weeks and eight weeks | Single Blood Pressure measurements, using the Omron M6 Comfort device |
| LDL Cholesterol | At the beginning, four weeks and eight weeks | Blood Sampling in Fasting conditions, in mg/dl |
Countries
Spain
Outcome results
None listed